Toggle Health Problems and D

Vitamin D sprayed inside cheeks 2X more response (poor gut) – RCT Oct 2015

RCT buccal spray for poor gut - Oct 2015

Radomized two way cross over study for comparison of absorption of vitamin D3 buccal spray and soft gelatin capsule formulation in healthy subjects and in patients with intestinal malabsorption
Nutrition Journal 2015, 14:114 doi:10.1186/s12937-015-0105-1
MC Satia1 milansatia at ethicare-cro.com, AG Mukim2, KD Tibrewala3 and MS Bhavsar4
1 Ethicare Clinical Trial Services, Ahmedabad, India
2 Mukim Medical And Nursing Homes, Ahmedabad, India
3 Tibrewala’s Clinic, Ahmedabad, India
4 Bhavsar’s Clinic, Ahmedabad, India

VitaminDWiki Summary

1000 IU given daily for 30 days to: healthy gut, poor gut

Buccal 10 ng
Oral 5 ng

Previous studies:
1000 IU ==> 5 ng ( has been 1000 IU ==> 10 ng)
Vitamin D as a pill: More response from powder than oil
Apparently: Buccal > Sublingual > Oral
Apparently:Topical > Oral
Apparently speed of response: Buccal > sublingual > oral

Amazon sells 100 Vitamin D sprays as of Dec 2018
Possible alternatives to spray:
Drops, water-soluable powder (Bio-Tech)
Which may provide as much response and as fast response as spray at much lower cost

Strangely this study failed to mention
The type of gel cap liquid - perhaps oil
When the caps were taken - far better if take Vitamin D orally with the largest meal of the day
What the caps were taken with - gel caps much better if taken with a fatty meal

See also VitaminDWiki



This was a crossover study

 Download the PDF from VitaminDWiki

Vitamin D deficiency has been proposed to contribute to the development of malabsorption diseases. Despite this, the vitamin D status of these patients is often neglected. The objective of the present work was to compare the absorption of vitamin D 3 through the oral route by comparing a 1000 IU soft gelatin capsule and a 500 IU buccal spray (delivering 1000 IU in two spray shots) in healthy subjects and in patients with malabsorption disease.

An open label, randomized, two-periods, two-way cross over study was conducted, first in healthy subjects (n = 20) and then in patients with malabsorption syndrome (n = 20). The study participants were equally divided and received either of the treatments (buccal spray, n = 7; soft gelatin capsule, n = 7; control, n = 6) in Period I for 30 days. After washout of another 30 days, the treatments were changed in crossover fashion in Period II. Fasting blood samples were collected to measure baseline 25-hydroxyvitamin D [25(OH)D] levels in all participants at day 0 (Screening visit), day 30 (completion of period I), day 60 (end of wash out and initiation of period II) and day 90 (completion of period II). Safety was evaluated by hematology and biochemistry analyses. Statistical analyses was performed using differences of mean and percentage change from baseline of 25(OH)D levels between two formulation by two tailed Paired t-test with 95 % confidence interval.

In healthy subjects, the mean increase in serum 25(OH)D concentration was 4.06 (95 % CI 3.41, 4.71) ng/ml in soft gelatin capsule group and 8.0 (95 % CI 6.86, 9.13) ng/ml in buccal spray group after 30 days treatment (p < 0.0001). In patients with malabsorption disease, the mean increase in serum 25(OH)D concentration was 3.96 (95 % CI 2.37, 5.56) ng/ml in soft gelatin capsule group and 10.46 (95 % CI 6.89, 14.03) ng/ml in buccal spray group (p < 0.0001).

It can be concluded from the results that the buccal spray produced a significantly higher mean serum 25(OH)D concentration as compared to the soft gelatin capsule, in both healthy subjects as well as in patients with malabsorption syndrome over a period of 30 days administration in a two way cross over study. Treatments were well tolerated by both subject groups

New buccal spray review proposed Dec 2018

Comparative effectiveness of vitamin D supplementation via buccal spray versus oral supplements on serum 25-hydroxyvitamin D concentrations in humans: a systematic review protocol.
JBI Database System Rev Implement Rep. 2018 Dec 3. doi: 10.11124/JBISRIR-2017-003907Pritchard L1,2, Lewis S3, Hickson M2.

This page was renamed on Dec 2018. There have actually been 9431 visitors to this page since it was originally made

Created by admin. Last Modification: Thursday October 17, 2019 01:13:09 GMT-0000 by admin. (Version 18)

Attached files

ID Name Comment Uploaded Size Downloads
6124 Buccal F1.jpg admin 31 Oct, 2015 08:43 64.48 Kb 2276
6123 Buccal F2.jpg admin 31 Oct, 2015 08:20 26.11 Kb 2279
6122 Buccal capsule.pdf PDF 2015 admin 31 Oct, 2015 08:20 882.63 Kb 1002